Investigating how dimethyl fumarate may help treat difficult-to-control epilepsy
Evaluating the disease modifying properties of dimethyl fumarate (DMF) for the prevention and treatment of pharmacoresistant epilepsy
['FUNDING_OTHER'] · UNIVERSITY OF WASHINGTON · NIH-10785216
This study is looking at how a medication called dimethyl fumarate (DMF) might help people with hard-to-treat epilepsy by boosting brain health and possibly improving seizure control and thinking skills.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10785216 on ClinicalTrials.gov |
What this research studies
This research explores the potential of dimethyl fumarate (DMF) to modify the course of pharmacoresistant epilepsy, a condition where standard medications fail to control seizures. The study will assess how DMF can enhance the brain's antioxidant defenses and potentially improve seizure control and cognitive function. By administering DMF at different stages of epilepsy, researchers aim to determine its effectiveness in preventing or reversing the disease's progression. The approach includes testing various doses in animal models to establish optimal treatment protocols.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from pharmacoresistant epilepsy who have not responded to standard antiseizure medications.
Not a fit: Patients with epilepsy that is well-controlled by existing medications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve seizure control and quality of life for patients with drug-resistant epilepsy.
How similar studies have performed: Previous studies have shown promising results with similar antioxidant approaches in animal models, suggesting potential for success in this novel application.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WHITE, H STEVE — UNIVERSITY OF WASHINGTON
- Study coordinator: WHITE, H STEVE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.